Current treatment modalities for pancreatic carcinoma afford only modest survival benefits.
Abstract
Current treatment modalities for pancreatic carcinoma afford only modest survival benefits.
TRAIL, as a potent and specific inducer of apoptosis in cancer cells, would be a promising new treatment option. However, since not all pancreatic cancer cells respond to TRAIL, further improvements and optimizations are still needed. One strategy to improve the effectiveness of TRAIL-based therapies is to specifically target one of the two cell death inducing TRAILreceptors, TRAIL-R1 or TRAIL-R2 to overcome resistance. To this end, we designed constructs expressing soluble TRAIL (sTRAIL) variants that were rendered specific for either TRAIL-R1 or TRAIL-R2 by amino acid changes in the TRAIL ectodomain. When we expressed these constructs, including wild-type sTRAIL (sTRAIL wt ), TRAIL-R1 (sTRAIL DR4 ) and TRAIL-R2
(sTRAIL DR5 ) specific variants, in 293 producer cells we found all to be readily expressed and secreted into the supernatant. These supernatants were subsequently transferred onto target cancer cells and apoptosis measured. We found that the TRAIL-R1 specific variant had higher apoptosis-inducing activity in human pancreatic carcinoma Colo357 cells as well as PancTu1 cells that were additionally sensitized by targeting of XIAP. Finally, we tested TRAIL-R1 specific recombinant TRAIL protein (rTRAIL DR4 ) on Colo357 xenografts in nude mice and found them to be more efficacious than rTRAIL wt . Our results demonstrate the benefits of
Introduction
The TNF-related apoptosis-inducing ligand (TRAIL/Apo-2L) was identified in the 1990s based on its sequence homology to other members of the TNF superfamily and is a type II transmembrane protein that can rapidly induce apoptosis. [1] [2] [3] [4] It has been mostly used as a recombinant and soluble protein produced in bacteria and is made up of the TRAIL ectodomain that corresponds to amino acid 114 to 281 of the TRAIL amino acid sequence. It is usually referred to as recombinant TRAIL (rTRAIL) or simply TRAIL. [5] [6] [7] An important and unique characteristic of TRAIL is its ability to selectively trigger receptor-mediated apoptosis in cancer cells but not in normal cells. 8 For this reason, TRAIL has been extensively studied as an anticancer reagent. TRAIL interacts with an intricate receptor system consisting of two apoptosisinducing agonistic death receptors, death receptor 4 (DR4/TRAIL-R1) and death receptor 5
(DR5/TRAIL-R2), and three antagonistic or decoy receptors, decoy receptor 1 (DcR1/TRAIL-R3), decoy receptor 2 (DcR2/ TRAIL-R4), and the soluble receptor osteoprotegerin (OPG). 9 TRAIL binds as homotrimer to DR4 and DR5, which results in trimerization of the receptors and this leads to the recruitment of Fas-associated death domain (FADD), which in turn allows binding and activation of the initiator caspase, caspase-8. Mature caspase-8 molecules are capable to activate downstream effector caspases, which then execute apoptosis. [10] [11] [12] DcR1 lacks a death domain and DcR2 contains a truncated death domain, so the binding of TRAIL to these receptors does not induce apoptosis but could instead prevent apoptosis by sequestering available TRAIL or by interfering with TRAIL-R1 or TRAIL-R2 signaling complexes. [13] [14] [15] OPG is a secreted protein that functions as a decoy receptor for RANKL, 16 but may also act as decoy receptor for TRAIL and protect against apoptosis. 17 The resistance of normal, non-transformed cells to TRAIL-induced apoptosis is likely regulated at more levels than just presence of decoy receptors, but decoy receptors may be responsible for the unresponsiveness of some cancer cells. 18 Consequently, one potential way of improving the therapeutic efficacy of TRAIL is to generate agents that act in a TRAIL-receptor specific way, preferring one of the two death receptors and potentially avoiding the decoy receptors. To this end, agonistic antibodies directed against one of the two apoptosis-inducing TRAIL-receptors have been developed and tested in various experimental systems as well as in the clinic. [19] [20] [21] [22] In addition, engineered variants of TRAIL, containing specific amino acid changes leading to specific targeting of TRAIL-R1 or TRAIL-R2 have been developed and have shown enhanced anti-tumor properties in-vitro and in-vivo. [23] [24] [25] [26] [27] [28] [29] [30] [31] This is of particular interest in the case of pancreatic cancer as previous studies have shown that pancreatic tumor cells preferentially use TRAIL-R1 to execute TRAIL-induced apoptosis. 32, 33 While these studies were carried out with agonistic antibodies against TRAIL-R1, TRAIL variants that possess specificity for TRAIL-R1 might hold important advantages such as the fact that they are smaller than antibodies and might therefore better able to reach and infiltrate growing tumors. Moreover, such proteins can be further engineered and optimized to increase activity, specificity and stability, and are potentially easier to produce and to test. Therefore, we generated TRAIL-receptor specific TRAIL variants based on earlier published amino acid sequence changes 24, 26, [28] [29] [30] and tested them on pancreatic cancer cells in-vitro and in-vivo. We utilized recombinant TRAIL (rTRAIL) variant proteins as well as a gene expression system that we described previously and gives rise to secreted and soluble TRAIL (sTRAIL). 27, 34, 35 This system, in principle, also allows for high-throughput analyses of TRAIL variants as new mutants
would not have to be expressed in bacteria and the protein purified before they can be tested on tumor cells and can also be integrated into various gene and cellular delivery vehicles. Here, we
show that both rTRAIL and sTRAIL variants directed against TRAIL-R1 possess higher apoptosis inducing activity in pancreatic cancer cells as compared to TRAIL-R2 specific variants and wild-type rTRAIL and sTRAIL. Thus, our study highlights that TRAIL-R1 specific variants constitute a potential improvement to conventional TRAIL therapies and might be able to overcome apoptosis resistance particularly in pancreatic cancers.
Results

TRAIL-receptor specific sTRAIL variants are expressed and secreted
DNA fragments encoding the signal peptide of the human fibrillin-1 gene (hFIB) gene, the Furin cleavage site (Furin CS), an Isoleucine zipper (ILZ) and the ectodomain of TRAIL (aa114-aa281; sTRAIL) were ligated together (Fig. S1 ). The hFIB signaling peptide leads to effective secretion of sTRAIL while the Furin CS mediates the removal of the signal peptide, while the ILZ forces the formation of trimeric sTRAIL, which has higher activity than monomeric sTRAIL. In addition to the common wild-type TRAIL construct (sTRAIL wt ) containing the consensus TRAIL cDNA sequence, we engineered one TRAIL-R1 (DR4) specific sTRAIL variant, termed sTRAIL DR4 and one specific for TRAIL-R2 (DR5), labeled sTRAIL DR5 (Fig. S2 ). Both sTRAIL DR4 and sTRAIL DR5 contained only one amino acid exchange, namely S159R and D269H, respectively (Fig. 1A) . 27 These two expression cassettes together with sTRAIL wt were cloned into pCDNA3.1 and along an EGFP control plasmid were transfected into 293 cells. Subsequent
Western blot analyses demonstrated that the two sTRAIL variants were expressed (Fig. 1B) and ELISA measurements of the 293 cell supernatants revealed that sTRAIL variants were indeed secreted (Fig. 1C) . The results demonstrated that the different sTRAIL variants were expressed and secreted to approximately the same levels as sTRAIL wt and that our expression system can be used as an alternative to recombinant proteins as part of gene and cellular therapeutic approaches.
In addition, the system serves as an easy test system for novel TRAIL variants or other therapeutic proteins without the need for laborious and time-consuming recombinant protein production and purification. DR5 and sTRAIL DR4 , respectively, harvested the supernatant media after 48 h, measured the sTRAIL concentration by ELISA and applied 8 ng/ml, 2 ng/ml, 0.5 ng/ml and 0.25 ng/ml onto Colo357 pancreatic cancer cells. After 24 h exposure to the sTRAIL variants we measured apoptosis. We found that at 8 ng/ml the three sTRAIL types (sTRAIL wt , sTRAIL DR5 and sTRAIL DR4 ) had very similar apoptosis-inducing activities ( Fig. 2A ).
Even though there was a trend towards increased cell death with sTRAIL DR4 , the difference was not significant. Added onto Colo357 cells at 2 ng/ml, sTRAIL DR4 triggered relatively more apoptosis than sTRAIL DR5 , but still provided no significant advantage over sTRAIL wt ( Fig 2B) .
However, at lower concentrations of sTRAIL DR4 (0.5 ng/ml and 0.25 ng/ml) it showed significantly higher levels of apoptosis as compared to sTRAIL wt and sTRAIL DR5 ( Fig. 2C and   2D ).
Moreover, in HeLa cervical cancer cells and HL-60 acute myeloid leukemia (AML) cells, we also found a preference to undergo apoptosis via TRAIL-R1, confirming results with purified recombinant TRAIL variant protein ( Fig. 2E and 2F ).
36, 30
Effects of rTRAIL DR4 on pancreatic cancer cells in-vitro
Next, we tested recombinant rTRAIL DR4 and rTRAIL wt protein on Colo357 cells. These proteins were generated and purified as described previously. 37 We applied the two proteins at a concentration of 100 ng/ml for 24 h before we measured apoptosis. The results reveal that rTRAIL DR4 led to significantly more apoptosis than rTRAIL wt in Colo357 cells corroborating our result with the sTRAIL variants (Fig. 3A) .
As 54 or they can be used in connection with cellular delivery vehicles such as mesenchymal stem cells (MSCs) that can infiltrate tumor tissues where they produce and secrete sTRAIL, which in turn acts on the neighboring cancer cells. 35, 55, 56 In the present study we initially transfected our TRAIL constructs into 293 cells that produced and secreted the different sTRAIL variants. After harvesting of the sTRAIL containing supernatants, measuring and normalizing of TRAIL concentrations, the supernatants were transferred onto cancer cells and apoptosis measured. We could show that these expressed and secreted variants behaved similarly to the equivalent recombinant proteins and can therefore be used inside of gene and cell therapeutic vectors providing the same specificity for TRAIL-R1 and TRAIL-R2, respectively.
In addition, this system allows for faster and more effective testing of potential further sTRAIL variants sparing the expensive and time-consuming need for purification of recombinant proteins from bacterial lysates. Numerous new TRAIL variants could be generated by PCR-based random mutagenesis, 57 cloned into our expression plasmid backbone and directly tested for their activity and specificity on cancer cells after transfection into 293 cells. Thus, our system could greatly enhance the search for optimized TRAIL variants and possibly other therapeutic proteins.
Having demonstrated the general utility of our TRAIL variants and in particular the superior However, the overall efficacy of the rTRAIL DR4 protein still leaves room for improvements such as integration of an ILZ domain or additional changes to the protein sequence to make the protein more stable and/or more active in-vivo. Our expression system as discussed above is well suited to identify such novel variants. Moreover, cellular delivery vehicles such as MSCs could be used to enhance availability of TRAIL in tumor tissues and TRAIL could be combined with conventional chemotherapeutic drugs for increased anti-tumor effects. 3, 35, 55, 58 In summary, our results demonstrate that TRAIL-receptor specific TRAIL variants are a significant improvement and represent a significant step forward to increase the potential for clinical tests and use of MSC-based delivery of TRAIL as part of a tumor-specific and patient-tailored therapy. In particular aggressive pancreatic cancer that is difficult to treat successfully is a possible target for such novel treatment approaches.
Materials and Methods
Reagents and cell culture: All chemicals, unless otherwise stated, were purchased from Sigma (St. Louis). Antibodies used in this study were sheep anti-CuZnSOD (The Binding Site) and rabbit anti-TRAIL (Peprotech) mouse anti-XIAP (BD Bioscience). Peroxidase-conjugated secondary antibodies were anti-mouse, anti-rabbit and anti-sheep (Santa Cruz).
Human cervix carcinoma HeLa cells (ATCC), human pancreatic cancer PancTu1 cells (gift from
Simone Fulda) as well as human embryonic kidney 293 cells (Life Technologies) were grown in Dulbecco's modified eagle medium (DMEM) supplemented with 10% FBS, 100 U/ml penicillin and 100 g/ml streptomycin. HL-60 and Colo357 (gifts from Eva Szegezdi) were grown in RPMI-1640 medium supplemented with 10% FBS, 100 U/ml penicillin and 100 g/ml streptomycin.
Generation of TRAIL constructs:
Generation of sTRAIL constructs and site-directed mutagenesis have been previously described. 27 Further information and details can be found in the Supplementary Material and Methods section.
Apoptosis assay Apoptosis was measured according to Nicoletti et al. 59 and has been described previously 60 .
Transfection of 293 cells:
For the transfection of 293 cells (5x10 5 cells/well) we used the calcium phosphate transfection method which has been previously described. 27 Supernatants of transfected 293 cells were cleared by centrifugation and diluted to determine the TRAIL concentration by ELISA.
Animal studies: Ten week old female CD1 nu/nu mice (Charles River, Wilmington, MA) were injected with 5x10 6 Colo357 cells in 200 µl PBS. After ten days and when tumors were palpable the animals were intraperitoneally daily injected with purified rTRAIL (wt and DR4) at a concentration of 5 mg/kg over a period of 10 days. The growth of the tumors was followed over 23 days. The tumor volume was calculated using three different diameters and the formula:
π/6*(d1*d2*d3). The animal studies were performed according to national laws and covered by license.
Histological analyses: Tumor, liver, bone marrow and spleen samples taken during necropsy were fixed in 10% neutral-buffered formalin, paraffin embedded and 4-μm sections were stained with hematoxylin and eosin (H&E). Bone marrow samples were decalcified before processing.
Additionally Masson's Trichrome staining was carried out on tumor sections as follows. Slides were rinsed and placed in Bouin's solution overnight at room temperature. The next day, slides were washed, stained with Weigert Hematoxylin for 10 min, rinsed in distilled water and stained with Biebrich scarlet-acid fuchsin for 5 min followed with immersion in phosphomolybdic/phosphotungstic acid solution for 15 min and stained with aniline blue for 5 min. Slides were then rinsed, dehydrated with 95% and absolute alcohol and mounted.
Western Blot: Western blots were carried out as described previously. 61 Briefly, cells were harvested and lyzed in cell lysis buffer. Proteins were separated by SDS-PAGE and transferred onto PVDF membranes (GE Healthcare Biosciences). Primary and secondary antibodies were diluted in TBS, 0.1% Tween and 3% BSA. Bands were visualized with ECL Western blotting Substrate (Pierce).
TRAIL Enzyme-linked Immunosorbent Assay (ELISA):
To examine secreted sTRAIL, the culture supernatants of transfected 293 cells were cleared by centrifugation at 2,000 g for 20 min.
The supernatants were diluted 20-fold and a commercial TRAIL ELISA kit (R&D Systems) was used following the manufacturer's instructions.
RNAi knock-down constructs and stable cell line generation:
The following small hairpin (sh)
RNA motif was used to target: XIAP (5´-GTGGTAGTCCTGTTTCAGC-3') and has been previously described. 39 Sense and antisense oligos containing the sh-sequence and 5' overhang representing a restricted BbsI site and EcoRI site on the 3' side were hybridized to generate 
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The sTRAIL constructs
The soluble portion of human TRAIL (amino acids 114-281; sTRAIL) was first subcloned into the NheI/NotI sites of an EcoR1-cut and re-circularized pDRIVE vector (Qiagen). First, the sTRAIL fragment was amplified by PCR from a pcDNA3 plasmid containing the fulllength cDNA of TRAIL (aa1-aa281). The following primers with Nhe1 and Not1 overhangs were used: Forward 5'-GCTAGCGTGAGAGAAAGAGGTCCTCAGAGAG-3'; Reverse 5'-GCGGCCGCTTAGCCAACTAAAAAGGCCCCGA-3'. The PCR fragment was cloned into a normal pDRIVE (Qiagene) vector, released with Nhe1 and Not1 and then ligated into the re-circularized pDRIVE plasmid that was opened up with Nhe1 and Not1. The plasmid was called pDRIVE.TRAIL-114. Subsequently, the fragments for the signal peptide from the human fibrillin 1 gene (aa1-aa27), a Furin cleavage site (aa28-aa37) and the isoleucine zipper (aa38-aa74) were cloned into pDRIVE.TRAIL-114 with BamH1/EcoR1, EcorR1/Sal1 and Sal1/Nhe1, respectively. These fragments were generated by hybridizing corresponding sense and antisense oligonucleotides with the respective restriction endonuclease overhangs listed above. The amino acid sequence of the resulting sTRAIL transgene product is depicted in Fig. S1 .
TRAIL variants, sTRAIL DR5 (D269H) and sTRAIL DR4 (S159R) were generated using the Quick-Change site-directed mutagenesis kit (Stratagene, La Jolla, CA) and confirmed by DNA sequencing Fig. S2 . 
